Syndicated Research Studies

Antibody Drug Conjugates Market Growth & Trends The global antibody drug conjugates market size is expected to reach USD 24.01 billion by 2030, registering a CAGR of 9.2% during the forecast period, according to a new report by Grand View Research, Inc. The presence of strong pipeline products and strategic initiatives undertaken by the key players are expected to drive the market growth during the forecast period. Key players such as ADC Therapeutics, Seagen. Inc., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., AstraZeneca, Daiichi Sankyo, and others are collaborating to develop and commercialize products. For instance, in February 2022, Mersana Therapeutics, partnered with Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson Inc., for the research and development of novel ADCs to treat various cancers. Under this agreement, Janssen will pay Mersana Therapeutics USD 40.0 million upfront and potentially more than USD 1.0 billion...

Antibody Drug Conjugates Industry Overview The global  antibody drug conjugates market  size is expected to reach over USD 22.87 billion by 2030, registering a CAGR of 16.4% during the forecast period, according to a new report by Grand View Research Inc. The presence of strong pipeline products and strategic initiatives undertaken by the key players are expected to drive the market growth during the forecast period. Antibody Drug conjugates Market Segmentation Grand View Research has segmented the global antibody-drug conjugates market based on the application, technology, and region: Based on the Application Insights, the market is segmented into Blood Cancer, Breast Cancer, Urothelial Cancer & Bladder Cancer, and Other Cancer. Breast cancer accounted for the largest revenue share in 2021 owing to the relatively high prevalence of the disease worldwide. According to WHO, there were around 2.26 million new breast cancer cases diagnosed worldwide in 2020, and estim...